Study findings on brain metastasis therapy are outlined in reports from University of South Florida, H. Lee Moffitt Cancer Center

Data detailed in "Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)" have been presented. Researchers in the United States conducted a study "To determine if high-dose melatonin for Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) Class 2 patients with brain metastases improved survival over historical controls, and to determine if the time of day melatonin was given affected its toxicity or efficacy. RTOG 0119 was a phase II randomized trial for this group of patients. RTOG RPA Class 2 patients with brain metastases were randomized to 20 mg of melatonin, given either in the morning...

Want to see the full article?

• Purchase this article for only $3.00